Vantage logo

Merck sees potential in Peloton 

Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…


Vantage logo

Abbott shifts to tricuspid repair

First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?

Company Events


Vantage Homepage